Remedium Lifecare is currently trading at Rs. 15.74, up by 1.34 points or 9.31% from its previous closing of Rs. 14.40 on the BSE.
The scrip opened at Rs. 14.50 and has touched a high and low of Rs. 16.00 and Rs. 14.45 respectively. So far 2406684 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 44.92 on 02-Aug-2023 and a 52 week low of Rs. 14.32 on 26-Jul-2024.
Last one week high and low of the scrip stood at Rs. 19.00 and Rs. 14.32 respectively. The current market cap of the company is Rs. 631.41 crore.
The promoters holding in the company stood at 1.11%, while Non-Institutions held 98.89% stake in the company.
Remedium Lifecare has entered into a strategic agreement with Angel Partners, UK, effective July 29, 2024, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, effective July 29, 2024.
Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at $20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. The company has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners.
Remedium Lifecare is pharmaceutical company aligned across two business verticals viz. Products and Services.
| Company Name | CMP |
|---|---|
| Redington | 235.90 |
| Amrapali Industries | 35.09 |
| Adani Enterprises | 2920.25 |
| Rashi Peripheral | 558.60 |
| PDS | 306.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: